PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical...
Hence then, the article about laminar pharma announces last patient last visit in lam561 phase 2b 3 trial for newly diagnosed glioblastoma patients was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients )
Also on site :
- CBS To Switch Affiliation From Nexstar To Hearst TV & Forum Communications Stations In A Half Dozen Markets
- Millions of Eggs Sold at Kroger and Other Stores Recalled Over Salmonella Risk
- Mexican Institute of Sound & Meridian Brothers Are Taking Their Tropical Madness on Tour: ‘I’ve Never Faced Such a Huge Challenge’